IN THE CLAIMS


- 1. (AMENDED) A method of treating a proliferative disease breast cancer, lung cancer, pancreatic cancer, colon cancer, myeloid leukemia, melanoma, thyroid follicular cancer, bladder carcinoma, glioma, myelodysplastic syndrome, ovarian cancer or prostate cancer in a patient in need of such treatment, comprising administering to said patient, a therapeutically effective amount of a combination of (1) a liposomal anthracycline composition in association with and (2) a growth factor receptor inhibitor. Trastuzumab; wherein said Trastuzumab is administered prior to, concurrently with or after the administration of said liposomal anthracycline composition; and wherein said liposomal anthracycline composition is pegylated liposomal doxorubicin comprising:
 - a) doxorubicin HCl;
- b) N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt;
 - fully hydrogenated soy phosphatidylcholine;
 - d) cholesterol;

histidine, hydrochloric acid and/or sodium hydroxide, ammonium sulfate, and sucrose; wherein the weight percentage ratio of a:b:c:d is about 1.0 :1.60 : 4.80 : 1.60 mg/mL respectively


- 2. (AMENDED) The method of Claim 1, wherein said growth factor receptor inhibitor is an antibody directed against the extracellular domain of a growth factor receptor, and said patient is a treatment experienced patient having a proliferative disease and/or has at least one cardiac risk factor and/or has had previous anthracycline therapy.
- 3. (Original) The method of Claim 2, further comprising an additional antineoplastic agent.
 - 4. Cancel without prejudice.

BEST AVAILABLE COPY


5. Cancel without prejudice



- 6. Cancel without prejudice.
- 7. Cancel without prejudice.
- 8. (AMENDED) The method of Claim [[6]] 2 wherein the pegylated liposomal anthracycline composition and the antibody directed against the extracellular domain of a growth factor receptor Trastuzumab are administered sequentially.
- 9. (AMENDED) The method of Claim [[6]] 2 wherein the pegylated liposomal anthracycline composition is administered first.
- 10. (AMENDED) The method of Claim [[6]] 2 wherein the antibody directed against the extracellular domain of a growth factor receptor Trastuzumab is administered first.
 - 11. Cancel without prejudice.
 - 12. Cancel without prejudice.
 - 13. Cancel without prejudice.
- 14. (AMENDED) The method of Claim [[11]] 3 wherein the additional antineoplastic agent is selected from the group consisting of: Uracil mustard, Cyclophosphamide, Ifosfamide, Melphalan, Chlorambucil, Temozolomide, 5-Fluorouracil, Fludarabine phosphate, Gemcitabine, Paclitaxel, Docetaxel, Interferons, Etoposide, Tamoxifen, Leuprolide, Flutamide, Toremifene, Cisplatin, Carboplatin, Navelbene, CPT-11, Anastrazole, Letrazole, and Capecitabine.
- 15. (AMENDED) The method of Claim [[11]] 3 wherein (1) the pegylated liposomal anthracycline composition, (2) the antibody directed against the extracellular domain of a growth factor receptor Trastuzumab, and (3) the additional antineoplastic agent are administered sequentially.



- 16. (AMENDED) The method of Claim [[11]] 3 wherein the additional antineoplastic agent is Cyclophosphamide.
 - 17. Cancel without prejudice.
 - 18. Cancel without prejudice.
- 19. (AMENDED) The method of claim 4 Claim 1 wherein the pegylated liposomal anthracycline composition is administered in the amount of about 20 to about 50 mg/m², given over a time period of about 45 to about 90 minutes, every three to four weeks.
- 20. (AMENDED) The method of claim 1 wherein the antibody directed against the extracellular domain of a growth factor receptor Trastuzumab is administered first in the amount of about 2 to about 6 mg/kg given once over a time period of about 60 to about 90 minutes and subsequently administered in the amount of about 2 to about 6 mg/kg given over a time period of about 60 to 90 minutes every one to four weeks.
- 21. (AMENDED) The method of claim 5 Claim 3 wherein the additional antineoplastic agent is administered in the amount of about 400 to about 600 mg/m² given over a time period of about 20 to about 60 minutes every two to four weeks.
 - 22. Cancel without prejudice.
 - 23. Cancel without prejudice.
 - 24. (AMENDED) The method of claim 11 Claim 3 wherein
- a) the pegylated liposomal doxorublcin composition is administered in the amount of about 20 to about 50 mg/m 2 given over a time period of about 45 to about 90 minutes every three to four weeks [[.]] \perp
- b) Trastuzumab is administered first in the amount of about 2 to about 8 mg/kg given over a time period of about 60 to about 90 minutes and subsequently



administered in the amount of about 2 to about 8 mg/kg given over a time period of about 60 to about 90 minutes every one to four weeks; and

- c) the additional antineoplastic agent is Cyclophosphamide and is administered in the amount of about 400 to about 600 mg/m² given over a time period of about 20 to about 60 minutes every two to four weeks.
- 25. (AMENDED) The method of claim Claim 24 wherein (1) the pegylated liposomal doxorubicin composition is administered first, followed by (2) Cyclophosphamide and then (3) Trastuzumab.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
TIMES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER:

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.